The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1
OSAKA, Japan and CAMBRIDGE, Massachusetts, May 14, 2025 – Takeda (TSE: 4502/NYSE:TAK) today announced that the New......